| Literature DB >> 32350737 |
Maja Kosecka-Strojek1, Ewa Sadowy2, Iwona Gawryszewska2, Joanna Klepacka3, Tomasz Tomasik3, Michal Michalik4, Waleria Hryniewicz5, Jacek Miedzobrodzki6.
Abstract
Coagulase-negative staphylococci, ubiquitous commensals of human skin, and mucous membranes represent important pathogens for immunocompromised patients and neonates. The increasing antibiotic resistance among Staphylococcus epidermidis is an emerging problem worldwide. In particular, the linezolid-resistant S. epidermidis (LRSE) strains are observed in Europe since 2014. The aim of our study was to genetically characterize 11 LRSE isolates, recovered mostly from blood in the University Children's Hospital in Krakow, Poland, between 2015 and 2017. For identification of the isolates at the species level, we used 16S rRNA sequencing and RFLP of the saoC gene. Isolates were characterized phenotypically by determining their antimicrobial resistance patterns and using molecular methods such as PFGE, MLST, SCCmec typing, detection of the ica operon, and analysis of antimicrobial resistance determinants. All isolates were multidrug-resistant, including resistance to methicillin, and exhibited so-called PhLOPSA phenotype. In PFGE, all isolates (excluding one from a catheter) represented identical patterns, were identified as ST2, and harbored the ica operon, responsible for biofilm formation. Linezolid resistance was associated with acquisition of A157R mutation in the ribosomal protein L3 and the presence of cfr gene. All isolates revealed new SCCmec cassette element composition. Recently, pediatric patients with serious staphylococcal infections are often treated with linezolid. The increasing linezolid resistance in bacterial strains becomes a real threat for patients, and monitoring such infections combined with surveillance and infection prevention programs is very important to decrease number of linezolid-resistant staphylococcal strains.Entities:
Keywords: Antibiotic resistance; ICU; Infections; Staphylococci
Mesh:
Substances:
Year: 2020 PMID: 32350737 PMCID: PMC7427702 DOI: 10.1007/s10096-020-03893-w
Source DB: PubMed Journal: Eur J Clin Microbiol Infect Dis ISSN: 0934-9723 Impact factor: 3.267
Primers used in the study
| Gene | Sequence (5′-3′) |
|---|---|
| TGCCCGTATTGGTTATCTCC | |
| TTCCTGCTCTGCATTGACTG | |
| ATGACTCTGATGGGGCTGTC | |
| CCTGCTCCAAGGTACAAAGC | |
| CAAGGTTTTGCAGGTGGATTG | |
| TGCTTCTTTACGGCGTGACTT | |
| AGGTGAGACCTCGGCCTAT | |
| CTTTCAACCAGATATACCAATCTTCA | |
| CTGGTAAAGTCCGTCAATGGAA | |
| TACCGTTGGATATTGCCTCTG | |
| ATTGACAGTCGCTACGAAAAGAAA | |
| ATCACTACCGGAAACAGCGAT | |
| AGGAGGTGGACTTTCGATGAC | |
| TGCAATTTCCTCCTTTCGCTTC | |
| TAAGAAGCGAAAGGAGGAAATTG | |
| ATTACGGGGCGCTTAAGAAC | |
| TTTCAGCATACCATTTTGCTTCC | |
| TAAAGGACATGCAGCAGACG | |
| 23S rRNA | CGGCGGCCGTAACTATAACGCAGCACTTATCCCGTCCATAC |
Patients characteristics
| Patient | Isolate no. | Date of isolate | Warda | Agea (days) | Weightb (g) | Length of hospitalizationa (days) | Antimicrobial treatmenta | No. of birth defectsb | No. of surgery proceduresb | Diagnosis associated with LRSEa (sepsis etc) | Leukocytosisa (leukocytes/mm3) | CRPa (mg/l) | PCTa (ng/ml) | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | K/15/9696; K/15/9821 | 28.11.2015; 2.12.2015 | ICU 1 | 23; 27 | 2900 | 23; 27 | Linezolid (Zyvoxid); meropenem (Meronem); vancomycin | 1 | 3 | Fever; circulatory centralization; oliguria; edema | 7180; 7250 | 57; 199.5 | 6.86; 1.98 | Discharge |
| 2 | K/16/3213 | 12.04.2016 | ICU 1 | 95 | 6400 | 7 | Linezolid (Zyvoxid); meropenem (Meronem) | 0 | 4 | Fever | 18,460 | 248 | 0.26 | Discharge |
| 3 | K/16/4573 | 30.05.2016 | ICU 2 | 236 | 3850 | 228 | Ceftriaxone (Lendacin) | 1 | 3 | Fever | 5100 | 8.2 | n/d | Discharge |
| 4 | K/16/8122 | 21.09.2016 | ICU 1 | 25 | 2740 | 15 | Linezolid (Zyvoxid); meropenem (Meronem); vancomycin | 3 | 1 | The patient’s condition is stable, suspected asymptomatic endocarditis, no extra symptoms | 4290 | 63 | 2.79 | Discharge |
| 5 | K/16/9005 | 22.10.2016 | ICU 1 | 268 | 915 | 15 | Linezolid (Zyvoxid); meropenem (Meronem) | 1 | 4 | Severe chronic condition; respiratory failure; suppuration of the postoperative wound | 17,340 | 55 | 0.11 | Discharge |
| 6 | K/3119 | 25.04.2017 | ICU 1 | 91 | 4820 | 68 | Ceftolozane/tazobactam (Zerbaxa) | 3 | 1 | Very severe condition, but stable, no extra symptoms | 8970 | 46.5 | 3.59 | Discharge |
| 7 | K/17/5479 | 12.07.2017 | ICU 1 | 337 | 2400 | 331 | Vancomycin | 3 | 6 | Chronic severe condition, no extra symptoms | 13,500 | 155.6 | 1.34 | Death (not due to infection) |
| 8 | O/17/6502 | 03.09.2017 | ICU 1 | 83 | 1880 | 76 | Ceftazidime (Fortum); biseptol | 1 | 3 | Chronic respiratory failure, inflammation around the central catheter | 7490 | 19 | n/d | Discharge |
| 9 | O/17/6612 | 07.09.2017 | ICU 2 | 70 | 3750 | 58 | Linezolid (Zyvoxid); levofloxacin; colistin | 2 | 3 | Chronic circulatory failure; respiratory failure, no extra symptoms | 10,130 | 65.8 | 0.28 | Discharge |
| 10 | K/17/7152 | 13.09.2017 | ICU 1 | 55 | 2300 | 54 | Linezolid (Zyvoxid) | 5 | 3 | Sepsis; fever, gastrostomy suppuration | 6670 | 245 | 0.24 | Death (not due to infection) |
LRSE linezolid-resistant S. epidermidis, CRP C-reactive protein, PCT procalcitonin
aAt LRSE isolation
bBefore LRSE infection
Fig. 1Dates of patient hospitalization and isolation of LRSE